Mark Lappe bought $849k of INBX
Chief Executive Officer at Inhibrx Biosciences, Inc.. 10,040 shares at an average of $84.56, traded Oct 14, 2026, filed Oct 14, 2026.
Score components
This filing reached EDGAR on Oct 14, 2026, so its score and components open to free visitors on Oct 21, 2026. The trade itself, the rows in the filing and the price context are public now.
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001366074-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +2,470 | $84.07 | $208k | 743,018 | 2 h ago |
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +2,470 | $85.00 | $210k | 745,488 | 2 h ago |
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By the Lappe Family Trust | +100 | $85.76 | $8,576 | 745,588 | 2 h ago |
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By Lappe Descendants' Trust | +2,449 | $84.07 | $206k | 167,449 | 2 h ago |
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By Lappe Descendants' Trust | +2,451 | $85.00 | $208k | 169,900 | 2 h ago |
| Oct 14, 2026 | POpen-market purchase Common Stockindirect: By Lappe Descendants' Trust | +100 | $85.76 | $8,576 | 170,000 | 2 h ago |
Related signals
Other insiders at Inhibrx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $999k 10,000 shares | +1% | |
| 46Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 53Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 31Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $164k 1,500 shares | -17% | |
| 30Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $115k 1,000 shares | -10% | |
| 44Moderate | Inhibrx Biosciences, Inc. | Douglas Forsyth director | $287k 2,500 shares | +1% | |
| 65Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $2.6M 25,000 shares | +4% | |
| 49Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $568k 5,000 shares | +1% | |
| 42Moderate | INBXsell Inhibrx Biosciences, Inc. | Viking Global Investors LP owner | $11M 350,000 shares | -22% | |
| 50Moderate | INBXbuy Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $1.5M 107,186 shares | +660% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.